Vaccine strain rSHA-[delta]200, and construction method and application thereof

Abstract

The invention provides a vaccine strain rSHA-[delta]200, and a construction method and application thereof, relates to that field of influenza vaccine. The vaccine strain rSHA-[delta]200 includes a HAgene that does not contain an NRT glycosylation site. The invention finds out the potential glycosylation sites on the HA protein through analysis, deletes glycosylation sites by site-directed mutagenesis technology, constructs HA expression plasmids with multiple glycosylation sites deleted, obtains recombinant vaccine strains by using 8 plasmid reverse genetic technology, and prepares antiserum. The rSHA-[delta]200 obtained in the invention is an ideal candidate for inactivated vaccine against H9 subtype AIV because of its good cross-immunity and serum cross-neutralization ability.

Description

technical field [0001] The invention relates to the technical field of influenza vaccines, in particular to a vaccine strain rSHA-Δ200 and its construction method and application. Background technique [0002] H9 subtype AIV is usually low-pathogenic avian influenza, which causes low poultry mortality. However, due to its wide distribution and fast transmission speed, the egg production of laying hens will drop sharply after infection, and broiler chickens will grow slowly. Reducing the feed-to-meat ratio has caused huge economic losses to the poultry farming industry. H9 subtype AIV infection is likely to lead to a sharp decline in the poultry's own immunity, resulting in concurrent or secondary infections of other bacteria or viruses leading to increased mortality. The H9 subtype AIV will also serve as the donor of the internal genes of other subtype influenza viruses, providing conditions for the generation of new influenza virus strains, triggering the outbreak of new i...

AI Technical Summary

Problems solved by technology

[0006] In order to solve the problem of continuous mutation of the existing H9 subtype AIV virus, the present invention provides a vaccine strain rSHA-△200 with strong immunity and good cross-immunity of H9 subtype AIV

Images